Advances in Type 2 Diabetes Care: Protecting Blood Vessel Health and Overcoming Obstacles to Insulin Therapy

Journal of Diabetes Investigation: Volume 8, Issue 3 Review

This issue highlights two critical themes in modern type 2 diabetes management: protecting cardiovascular health through blood vessel preservation and understanding the real-world barriers that prevent timely transitions to insulin therapy.

The featured research provides valuable insights on how linagliptin (a DPP-4 inhibitor) can improve the function of the inner lining of blood vessels, helping to guard against vascular complications. Concurrently, a large-scale observational study in Korea uncovers the common clinical and psychological reasons why both patients and physicians delay starting insulin—even when oral drugs are no longer sufficient to control blood glucose.

For patients, families, and healthcare providers, these findings emphasize that diabetes management extends far beyond daily blood glucose numbers. It involves active communication to overcome treatment hurdles and prioritizing therapies that support long-term heart and blood vessel health.

Disclaimer The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Clinical Research

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function

Authors: Fumika Shigiyama, Naoki Kumashiro, Masahiko Miyagi, Ryo Iga, Yuka Kobayashi, Eiichiro Kanda, Hiroshi Uchino, Takahisa Hirose

Research Objective

To evaluate and compare the impact of adding the DPP-4 inhibitor linagliptin to standard therapy versus increasing the dose of metformin on blood vessel function in adults with type 2 diabetes.

Methods

In this 16-week randomized, open-label trial, 96 patients with type 2 diabetes who were already taking 750 mg/day of metformin (and had HbA1c levels between 6.0% and 8.0%) were divided into three groups:

• Control Group (29 patients): Continued taking 750 mg/day of metformin.
• Metformin Group (26 patients): Increased metformin to 1,500 mg/day.
• Linagliptin Add-on Group (29 patients): Continued 750 mg/day of metformin and added 5 mg/day of linagliptin.

The researchers evaluated changes in endothelial function using flow-mediated dilation (FMD)—a non-invasive method measuring how well blood vessels dilate in response to blood flow changes.

Main Findings

Only the group taking the linagliptin add-on showed significant improvement in blood vessel dilation, with average FMD measurements increasing from 4.9% at baseline to 6.3% after 16 weeks. The other groups did not experience significant changes. Additionally, both the metformin-only and linagliptin add-on groups saw safe decreases in HbA1c levels. The positive change in blood vessel function was associated with a reduction in apolipoprotein B (a marker for cholesterol particles that can clog arteries), which decreased uniquely in the linagliptin group.

Clinical Significance

Linagliptin therapy not only helps manage blood sugar levels but also directly supports vascular health by improving the function of the inner blood vessel lining (the endothelium). This effect is likely linked to the reduction of atherogenic cholesterol carriers (apolipoprotein B).

Key Points for Patients

The "endothelium" is the delicate inner lining of your blood vessels. When it functions poorly, the risk of cardiovascular complications increases. If you have type 2 diabetes with mild-to-moderate high blood sugar, adding a medication like linagliptin to your current metformin therapy might provide an extra layer of protection for your cardiovascular system, beyond simply lowering your daily blood sugar readings.

DOI: https://doi.org/10.1111/jdi.12587
Read the original article →

Observational Study

Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents: A prospective observational DIPP-FACTOR study in Korea

Authors: Sin Gon Kim, Nam Hoon Kim, Bon Jeong Ku, Ho Sang Shon, Doo Man Kim, Tae Sun Park, Yong‐Seong Kim, In Joo Kim, Dong Seop Choi

Research Objective

To determine how long it takes to initiate insulin therapy in patients with uncontrolled type 2 diabetes and to pinpoint both patient- and physician-related factors that contribute to delays in starting insulin.

Methods

This large prospective disease registry study monitored 1,959 evaluable type 2 diabetes patients across 69 centers in Korea. All patients had used two or more oral diabetes medications over the past five years, had poorly controlled blood sugar (HbA1c ≥ 8% within the past six months), and had not yet started insulin. Researchers tracked insulin initiation over 12 months.

Main Findings

Only 20% of these patients started insulin during the 1-year study. Among those taking two oral medications, less than half (44.5%) had initiated insulin even after 6 years of eligibility. Key obstacles included:

• Patient-related barriers: Patients who delayed insulin were often older, had a shorter overall duration of diabetes, or had comparatively lower HbA1c levels. The main reasons patients refused insulin were the perceived inconvenience of therapy (51.6%) and fear of injections (48.2%).
• Physician-related barriers: Delayed initiation was linked to physicians aged 50–59, female physicians, and doctors seeing fewer than 1,000 patients per month. The primary physician-reported reasons for delaying therapy were patient refusal (33.6%) and worries about whether the patient would comply with the insulin regimen (26.5%).

Clinical Significance

A substantial delay in starting insulin exists for patients whose diabetes is poorly managed on multiple oral drugs. Addressing psychological barriers (such as needle phobias and lifestyle disruption concerns) and boosting physician-patient communication are critical steps toward improving outcomes.

Key Points for Patients

Starting insulin can be intimidating, but when oral medications are no longer working, delaying insulin can increase your risk of long-term diabetes complications. Concerns about pain, needles, or daily routine disruption are highly common and completely natural. Discussing these specific worries openly with your medical team can help you find modern, easy-to-use insulin options that fit your lifestyle.

DOI: https://doi.org/10.1111/jdi.12581
Read the original article →

Biomarkers, Genetic Markers, and Easier Insulin Resistance Tracking: JDI Research Review

Issue Research Summary

This issue of the Journal of Diabetes Investigation highlights key clinical and genetic advancements aimed at improving how we predict, diagnose, and monitor type 2 diabetes and its complications. The featured studies focus on identifying reliable biological markers to track nerve and kidney damage, testing genetic variants in specific populations, and simplifying the mathematical models doctors use to calculate insulin resistance.

Key takeaways from this issue include:

• Complication Markers: Research indicates that specific fat-tissue hormones (adipocytokines), particularly adiponectin, may help identify patients at higher risk for nerve complications (neuropathy).
• Genetic Clarifications: A large-scale analysis of serine racemase (SRR) gene variants in the Chinese Han population shows that these variants do not directly correlate with overall type 2 diabetes risk, emphasizing the need for robust verification of genetic markers.
• Simplified Diagnosis: A newly developed mathematical model allows clinicians to accurately estimate insulin resistance using routine metabolic data and standard sugar-tolerance tests, making precise care more accessible.

These findings pave the way for more personalized, efficient, and non-invasive methods to assess diabetes severity and prevent long-term complications.

Disclaimer The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Biomarkers & Complications

Association between serum adipocytokine levels and microangiopathies in patients with type 2 diabetes mellitus

Authors: Chan‐Hee Jung, Bo‐Yeon Kim, Ji‐Oh Mok, Sung‐Koo Kang, Chul‐Hee Kim

Research Objective:

To investigate the relationship between blood levels of adipocytokines (fat-tissue hormones, specifically adiponectin, leptin, and TNF-α) and small blood vessel complications (microangiopathies) such as nerve, eye, and kidney disease in patients with type 2 diabetes.

Methods:

The study evaluated 153 Korean patients with type 2 diabetes. The researchers measured fasting blood levels of adiponectin, TNF-α, and leptin, and checked participants for diabetic kidney disease (nephropathy), eye damage (retinopathy), and nerve damage (neuropathy).

Main Findings:

• Adiponectin levels were significantly lower in patients with kidney disease, but higher in those with eye or nerve damage.
• Leptin levels were significantly higher in patients suffering from nerve damage.
• TNF-α levels did not show any significant differences across any of the three complications.
• Crucially, patients with the highest levels of adiponectin were 4.3 times more likely to have diabetic nerve damage compared to those with the lowest levels.

Clinical Significance:

The differing levels of these hormones based on the presence of specific complications suggest they may serve as indicators for early nerve, kidney, or eye damage. In particular, elevated adiponectin in the blood was independently linked to diabetic nerve damage.

Key Points for Patients:

Hormones released by your fat tissues might hold clues to how diabetes is affecting your body. Identifying elevated levels of these hormones through simple blood tests may eventually help doctors catch nerve or kidney complications earlier, though further research is required to confirm a direct cause-and-effect relationship.

DOI: https://doi.org/10.1111/jdi.12144

Genetics

Association of serine racemase gene variants with type 2 diabetes in the Chinese Han population

Authors: Simin Zhang, Jianzhong Xiao, Qian Ren, Xueyao Han, Yong Tang, Wenying Yang, Xianghai Zhou, Linong Ji

Research Objective:

To evaluate whether specific genetic variations in the serine racemase (SRR) gene are associated with an increased risk of developing type 2 diabetes in the Chinese Han population.

Methods:

Researchers examined genetic data from 21,305 Chinese Han individuals. They analyzed two specific locations (variants rs391300 and rs4523957) on the SRR gene and compared genetic markers between 2,615 newly diagnosed type 2 diabetes patients and 5,029 healthy control participants.

Main Findings:

• The study found no direct association between these SRR gene variants and type 2 diabetes across the studied population.
• A broad meta-analysis also failed to confirm a link between the SRR gene and type 2 diabetes.
• However, healthy control subjects carrying specific versions of these genes did exhibit slightly higher blood glucose levels 30 minutes into an oral glucose tolerance test.

Clinical Significance:

This study clarifies that although the SRR gene might play a subtle role in how healthy individuals temporarily process glucose, these specific genetic variants are not reliable risk markers for predicting type 2 diabetes in the Chinese Han population.

Key Points for Patients:

Diabetes risk is highly complex, involving many different genes and lifestyle factors. While certain genes are occasionally linked to diabetes in smaller trials, larger studies like this one show that these specific genetic variants are not a reliable way to predict whether someone will develop type 2 diabetes.

DOI: https://doi.org/10.1111/jdi.12145

Diagnostic Methods

Accurate method to estimate insulin resistance from multiple regression models using data of metabolic syndrome and oral glucose tolerance test

Authors: Chung‐Ze Wu, Jiunn‐Diann Lin, Te‐Lin Hsia, Chun‐Hsien Hsu, Chang‐Hsun Hsieh, Jin‐Biou Chang, Jin‐Shuen Chen, Chun Pei, Dee Pei, Yen‐Lin Chen

Research Objective:

To create a highly accurate, practical, and convenient mathematical model to calculate insulin resistance in daily clinical settings, bypassing the need for complex, invasive laboratory procedures.

Methods:

The study enrolled 327 participants, dividing them into normal and abnormal glucose tolerance groups. Researchers used the "insulin suppression test" as the exact baseline standard. They built and tested five different mathematical models using combinations of standard patient parameters (age, sex, metabolic syndrome factors, and blood sugar/insulin levels during a standard oral glucose tolerance test).

Main Findings:

• The new mathematical formulas (specifically Model 5, which combines metabolic syndrome characteristics with a full oral sugar test) were highly accurate.
• These models outperformed standard clinical estimations currently used in practices (such as HOMA-IR and QUICKI).

Clinical Significance:

These updated formulas provide doctors with a more accurate, convenient, and reliable way to identify and monitor insulin resistance in routine practice, potentially leading to faster and more tailored treatment plans.

Key Points for Patients:

Accurately measuring how well your body uses insulin normally requires long and intensive laboratory tests. This research introduces a new, highly accurate mathematical method that allows doctors to calculate your insulin resistance using routine office records and a standard blood test, helping personalize your diabetes care with less hassle.

DOI: https://doi.org/10.1111/jdi.12155

Advancements in Diabetes Care: Monitoring, Cardiovascular Risk, and Personalized Management

Monthly Review: Journal of Diabetes Investigation (Vol.4, Issue 5)

Issue Summary (JDI Vol.4, Issue 5)

This issue of the Journal of Diabetes Investigation presents several key studies offering insights into improving diabetes management, predicting cardiovascular risks, and understanding the disease's varied impacts. Research highlights the benefit of structured self-monitoring for better long-term blood sugar control in insulin-treated patients. A notable study identifies serum adiponectin as a predictor for coronary heart disease risk in Japanese patients with type 2 diabetes, similar to Caucasians, suggesting a universal marker.

Furthermore, findings emphasize the importance of assessing visceral fat (fat around internal organs) over just body mass index (BMI) for effective weight-loss strategies to improve glycemic control, especially for those at risk of diabetes. The issue also delves into microvascular complications, revealing distinct cellular changes in the cornea (the clear front part of the eye) of type 2 diabetes patients, linked to disease duration and nerve damage.

Finally, a significant population study from Korea provides a snapshot of diabetes trends, showing increasing prevalence and improved control of blood pressure and lipids, though glycemic control (blood sugar levels) remains a challenge. These studies collectively underscore the ongoing efforts to enhance personalized care, refine risk assessment, and improve overall outcomes for individuals living with diabetes.

Disclaimer
The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Structured self‐monitoring of blood glucose reduces glycated hemoglobin in insulin‐treated diabetes

Research Objective
This study aimed to determine if structured self-monitoring of blood glucose (SMBG) could help improve blood sugar control in people with diabetes who are on insulin but whose blood sugar levels are not well-controlled.

Methods
Researchers assigned 86 insulin-treated patients to one of two groups: a routine testing group or a structured testing group. The structured group used a special chart to record their blood glucose levels seven times a day for three consecutive days each month. The main goal was to see changes in their HbA1c (a measure of average blood sugar over 2-3 months) after 3 and 6 months.

Main Findings
At 3 months, there was no significant difference in HbA1c between the groups. However, after 6 months, the structured testing group showed significantly better HbA1c levels compared to the routine testing group. Their HbA1c decreased by 0.5% (from 7.9% to 7.4%), while the routine group's HbA1c only decreased by 0.1% (from 7.9% to 7.8%). A majority (55%) of patients in the structured group were willing to continue this method, and they achieved an even greater HbA1c decrease of 0.7%.

Clinical Significance
These findings suggest that a structured approach to self-monitoring blood glucose can significantly improve long-term blood sugar control in people with insulin-treated diabetes.

Key Points for Patients
If you're managing diabetes with insulin, a more organized way of checking your blood sugar can be very helpful. Even a simple chart to record your levels a few days a month can lead to better overall blood sugar control over time. Consistent efforts can make a meaningful difference in your health.

DOI: https://doi.org/10.1111/jdi.12072

Serum adiponectin levels predict the risk of coronary heart disease in Japanese patients with type 2 diabetes

Research Objective
This study aimed to find out if levels of a protein called adiponectin in the blood can predict the risk of coronary heart disease (CHD) in Japanese patients with type 2 diabetes, similar to what has been observed in Caucasian populations.

Methods
Researchers followed 504 Japanese patients with type 2 diabetes for a median of 5.7 years. They used statistical methods (Cox proportional hazard analysis) to assess how baseline serum adiponectin levels related to the risk of developing new or recurrent CHD.

Main Findings
During the study period, 50 participants experienced CHD events. After accounting for other known heart disease risk factors, patients with the highest levels of serum adiponectin had a significantly reduced risk of CHD compared to those with the lowest levels (a 65% lower risk). Doubling the adiponectin level was associated with a 39% lower risk of CHD. This suggests a strong link between higher adiponectin and lower heart disease risk, independent of other factors.

Clinical Significance
High serum adiponectin levels are significantly associated with a lower risk of coronary heart disease in Japanese patients with type 2 diabetes. This confirms that adiponectin is an important predictor for CHD in this population, similar to previous findings in Caucasians.

Key Points for Patients
Adiponectin is a protein that appears to play a protective role against heart disease, especially in people with type 2 diabetes. Higher levels of this protein are linked to a lower risk of developing heart problems. This finding could help doctors identify patients at higher risk and potentially guide future treatments aimed at improving heart health.

DOI: https://doi.org/10.1111/jdi.12078

Weight reduction is associated with improvement of glycemic control in Japanese men, whose hemoglobin A1C is 5.6–6.4%, with visceral fat accumulation, but not without visceral fat accumulation

Research Objective
This study investigated whether weight reduction improves blood sugar control (measured by HbA1c between 5.6% and 6.4%) in Japanese men, specifically looking at how this is affected by whether they have visceral fat accumulation (fat around internal organs).

Methods
Researchers studied 798 Japanese men with HbA1c levels between 5.6% and 6.4%. They divided these men into groups based on their Body Mass Index (BMI) and estimated visceral fat area (eVFA). The study then looked at the relationship between changes in BMI and changes in HbA1c over one year.

Main Findings
Weight reduction (decrease in BMI) was associated with improved HbA1c levels, but this link was much stronger and more significant in men who had accumulated visceral fat (eVFA ≥100 cm²), regardless of their overall BMI. For men without significant visceral fat accumulation (eVFA <100 cm²), there was no clear association between weight change and HbA1c improvement.

Clinical Significance
These results suggest that assessing visceral fat levels, rather than just BMI, might be more important for identifying individuals who would benefit most from lifestyle changes aimed at weight reduction to improve or prevent diabetes.

Key Points for Patients
If you're looking to improve your blood sugar control or prevent diabetes, especially if your HbA1c is in the pre-diabetes range (5.6-6.4%), losing weight can be very effective. This study highlights that it's particularly beneficial if you have a lot of fat around your internal organs (visceral fat). Knowing your visceral fat levels might help you and your doctor decide on the best weight management strategy.

DOI: https://doi.org/10.1111/jdi.12084

Morphometric features of corneal epithelial basal cells, and their relationship with corneal nerve pathology and clinical factors in patients with type 2 diabetes

Research Objective
This study aimed to examine changes in the cells of the cornea (the clear, outer layer of the eye) in patients with type 2 diabetes and to see how these changes relate to nerve damage in the cornea and other health factors.

Methods
Researchers used a special microscope called a corneal confocal microscope to visualize the cells at the base of the corneal epithelium and the corneal nerve fibers in 75 patients with type 2 diabetes and 42 healthy individuals. They measured various features of these cells, such as their density, size, variability in size, and the space between them.

Main Findings
Patients with type 2 diabetes showed several changes in their corneal cells compared to healthy controls: decreased cell density, smaller cell area, greater variability in cell area, and wider spaces between cells. These cellular changes were linked to how long a person had diabetes, the presence of 'beading' (a sign of damage) in corneal nerve fibers, and factors related to blood clotting (like fibrinogen levels).

Clinical Significance
Type 2 diabetes induces specific structural changes in corneal epithelial basal cells. These changes appear to be related to the duration of diabetes, nerve damage in the cornea, and the blood's ability to clot. This research could offer new ways to understand and potentially detect diabetes complications affecting the eyes.

Key Points for Patients
Diabetes can affect many parts of your body, including your eyes, down to the cellular level. This study shows that the clear front layer of your eye (the cornea) undergoes subtle changes in people with type 2 diabetes. These changes are linked to how long you've had diabetes and signs of nerve damage in the eye. Understanding these changes might one day help doctors identify diabetes-related eye problems earlier.

DOI: https://doi.org/10.1111/jdi.12083

Increasing achievement of the target goals for glycemic, blood pressure and lipid control for adults with diagnosed diabetes in Korea

Research Objective
This study aimed to examine the trends in the prevalence (how common it is), treatment, and control of diagnosed diabetes among Korean adults from 1998 to 2010.

Methods
Researchers analyzed data from the Korean National Health and Nutrition Examination Survey (KNHANES) conducted between 1998 and 2010. They looked at how many adults had diagnosed diabetes and what percentage achieved target goals for HbA1c (less than 7.0%), blood pressure (less than 130/80 mmHg), and LDL cholesterol (less than 100 mg/dL), according to American Diabetes Association guidelines.

Main Findings
The prevalence of diagnosed diabetes in Korea significantly increased from 3.2% in 1998 to 6.4% in 2010. During this period, the proportion of patients meeting blood pressure and LDL cholesterol targets also significantly increased. However, the percentage of patients achieving their glycemic (blood sugar) goals did not significantly increase. While the number of individuals meeting all three targets (blood sugar, blood pressure, and cholesterol) improved, it still remained low (from 2.7% in 2005 to 8.7% in 2010).

Clinical Significance
While the prevalence of diagnosed diabetes in Korea has increased, significant progress has been made in controlling blood pressure and cholesterol levels. However, glycemic control remains a challenge, and there is still much room for improvement in achieving comprehensive management goals for people with diabetes.

Key Points for Patients
More and more people are being diagnosed with diabetes. While doctors and patients are getting better at controlling blood pressure and cholesterol, maintaining ideal blood sugar levels (HbA1c) remains a tough goal for many. This highlights the importance of working closely with your healthcare team to manage all aspects of your diabetes care, as meeting all goals is crucial for long-term health.

DOI: https://doi.org/10.1111/jdi.12077

Managing Diabetes Risks: From Blood Pressure Control and Early Screenings to Sleep Chronotypes

Advances in Diabetes Care: Comorbidities, Early Screening, Blood Pressure Stability, and Lifestyle Rhythms

In this review of the latest research, we explore crucial clinical findings that directly impact how patients and healthcare providers manage diabetes. Diabetes is rarely an isolated condition; its intersection with other chronic issues shape the daily experiences and health outcomes of those living with it.

Key themes highlighted in these recent studies include:

• Complex Comorbidities: An epidemiological study from Italy emphasizes how frequently conditions like hypertension coexist with diabetes, demanding integrated clinical care.
• Early Screening Milestones: A study in a Japanese population suggests that 1-hour post-load plasma glucose levels could serve as a valuable early warning indicator for future diabetes risk.
• Morning Blood Pressure Control: Research shows how specific medication choices, such as calcium channel blockers, can stabilize morning blood pressure fluctuations, lowering cardiovascular risks for individuals with type 2 diabetes.
• The Power of Sleep-Wake Cycles: For working individuals, being a "night owl" (eveningness) is linked to higher HbA1c levels and poorer sleep quality compared to those with natural "morningness" patterns.

Understanding these connections helps patients and families make informed decisions alongside their medical teams to improve long-term wellness and prevent complications.

Disclaimer
The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Epidemiology & Comorbidities

Prevalence and Comorbidities of Known Diabetes in Northeastern Italy

Research Objective:
The researchers sought to estimate how common diabetes is in northeastern Italy and to identify the other chronic health conditions (comorbidities) that most frequently coexist in hospitalized diabetic patients.

Methods:
Using administrative health data from 2010 to 2011 in the Friuli Venezia Giulia region, the authors calculated diabetes prevalence. They then used a data mining technique (association rule mining) to analyze diagnoses among 155,494 patients admitted to regional hospitals, looking specifically at the 9,358 patients who had diabetes.

Main Findings:
The estimated prevalence of known diabetes in 2010 was between 6.0% and 8.1%. However, this rate varied dramatically by age—affecting under 2% of people under age 60, but rising to over 20% in some elderly age groups. Among the hospitalized diabetic patients, the strongest medical pairing identified was the combination of diabetes and essential hypertension (high blood pressure), which occurred with the highest frequency and probability.

Clinical Significance:
The study highlights the intricate medical profile of patients with diabetes. It demonstrates that diabetes management cannot happen in a silo; clinicians must actively manage coexisting conditions, particularly high blood pressure, to ensure successful overall health outcomes.

Key Points for Patients:
If you have diabetes, you are at a higher risk for other health conditions, especially high blood pressure. Managing your cardiovascular health through lifestyle choices and prescribed treatments is just as vital as monitoring your daily blood sugar levels.

Authors: Francesca Valent, Silvia Tillati, Loris Zanier
DOI: 10.1111/jdi.12043 | Read the original article

Diagnostics & Risk Screening

Meaning of Upper Limit of Normal Range of Post-Load 1-Hour Plasma Glucose Level Defined by Oral Glucose Tolerance Test in Japanese Subjects

Research Objective:
To identify the optimal upper limit of normal for 1-hour blood sugar levels following an oral glucose tolerance test (OGTT) in a Japanese population, aiming to catch early signs of diabetes risk.

Methods:
The study enrolled 918 Japanese participants, dividing them into two groups based on their standard 2-hour post-load glucose level: a normal group (<140 mg/dL, 417 subjects) and an impaired group (≥140 mg/dL, 501 subjects). Statistical analysis (ROC curve) was used to determine the best cut-off value for the 1-hour glucose level.

Main Findings:
The ideal cut-off value for 1-hour post-load plasma glucose was determined to be 179 mg/dL. Among those whose 1-hour glucose was below 179 mg/dL, only 0.5% actually had diabetes. In contrast, among those whose 1-hour glucose reached or exceeded 179 mg/dL, 26.9% were diagnosed with diabetes. Additionally, a strong correlation was found between 1-hour and 2-hour glucose values.

Clinical Significance:
This suggests that 179 mg/dL serves as the upper limit of normal for 1-hour post-meal glucose in Japanese individuals. Exceeding this threshold indicates a elevated risk of developing diabetes in the future, even if standard 2-hour glucose tests appear normal.

Key Points for Patients:
When undergoing a glucose tolerance test, the 1-hour mark is highly informative. If your blood sugar spikes above 179 mg/dL at the 1-hour point, it is a warning sign that you may be at risk for diabetes later, allowing you to take early preventive actions.

Authors: Tadashi Iwao, Kenji Sakai, Eiji Ando
DOI: 10.1111/jdi.12060 | Read the original article

Cardiovascular Health & Pharmacology

Beneficial Effect of Calcium Channel Blockers on Home Blood Pressure Variability in the Morning in Patients with Type 2 Diabetes

Research Objective:
To examine if different classes of blood pressure medications affect morning home blood pressure fluctuations (variability) differently in patients with type 2 diabetes.

Methods:
The study compared three groups of hypertensive patients with type 2 diabetes: those taking calcium channel blockers (CCBs, n=44), those taking ARBs and/or ACE inhibitors (n=159), and those taking a combination of both classes (n=183). Fluctuations in morning systolic blood pressure were measured and analyzed using statistical regression models.

Main Findings:
Patients treated with calcium channel blockers had significantly lower morning blood pressure variability compared to those treated only with ARBs/ACE inhibitors. Further analysis confirmed that the use of CCBs was directly and independently correlated with a reduction in morning systolic blood pressure fluctuations.

Clinical Significance:
Wide fluctuations in blood pressure, especially in the morning, are associated with a higher risk of heart attacks and strokes. This study indicates that choosing calcium channel blockers might be highly beneficial for type 2 diabetes patients to stabilize morning blood pressure and potentially lower cardiovascular risks.

Key Points for Patients:
Blood pressure that swings wildly in the morning is dangerous for your blood vessels. If you have type 2 diabetes and high blood pressure, talk to your doctor about whether a calcium channel blocker could be a good option to help keep your morning readings steady.

Authors: Emi Ushigome, Michiaki Fukui, Masahide Hamaguchi, Toru Tanaka, Haruhiko Atsuta, Masayoshi Ohnishi, Yohei Oda, Masahiro Yamazaki, Goji Hasegawa, Naoto Nakamura
DOI: 10.1111/jdi.12052 | Read the original article

Lifestyle & Circadian Rhythm

Morningness–Eveningness Questionnaire Score Correlates with Glycated Hemoglobin in Middle-Aged Male Workers with Type 2 Diabetes Mellitus

Research Objective:
To investigate whether natural sleep-wake schedules (morning vs. evening preferences) correlate with blood sugar control and sleep quality in middle-aged male workers with type 2 diabetes.

Methods:
The study evaluated 101 Japanese male diabetic workers. They used the Morningness-Eveningness Questionnaire (MEQ) to evaluate whether they were "morning types" or "evening types," and the Pittsburgh Sleep Quality Index (PSQI) to measure sleep quality. Blood tests measured glycated hemoglobin (HbA1c) and cholesterol levels.

Main Findings:
Higher "morningness" scores (indicating an early-to-bed, early-to-rise lifestyle) were significantly linked to lower (better) HbA1c levels, higher HDL (good) cholesterol, and better overall sleep quality. Conversely, "evening type" workers (night owls) had significantly higher HbA1c levels (indicating poorer blood sugar control), higher LDL (bad) cholesterol, and worse sleep quality.

Clinical Significance:
This research establishes a direct link between circadian sleep preferences and metabolic health. It suggests that a late-night/evening lifestyle may contribute to poorer blood sugar management and cholesterol levels in working men with diabetes.

Key Points for Patients:
Your sleep habits matter! Being a "night owl" might make it more difficult to control your blood sugar levels. Trying to establish a regular, earlier sleep routine and improving your sleep hygiene could be powerful tools in helping manage your diabetes.

Authors: Masato Iwasaki, Takahisa Hirose, Tomoya Mita, Fumihiko Sato, Chiharu Ito, Risako Yamamoto, Yuki Someya, Tomoaki Yoshihara, Yoshifumi Tamura, Akio Kanazawa, Ryuzo Kawamori, Yoshio Fujitani, Hirotaka Watada
DOI: 10.1111/jdi.12047 | Read the original article

Diabetes Care Insights: Advancements in Neuropathy Detection, Automated Insulin Pumps, and Personalized Treatment Predictors

Journal of Diabetes Investigation: Vol. 17, Issue 2 Review

This issue highlights key advancements in managing diabetes and its complications, focusing on early detection methods, advanced treatment technologies, and personalized medical approaches. Neuropathy remains a core focus, with researchers identifying new, accessible, and objective ways to diagnose early nerve damage. Furthermore, we see how modern automated insulin pumps are significantly raising quality of life for those with type 1 diabetes, and how machine learning is helping clinicians predict which patients will benefit most from specific glucose-lowering therapies.

Key Takeaway: Future diabetes care is shifting towards highly customized treatment plans—utilizing technology and metabolic profiles to optimize patient outcomes.

Disclaimer The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Diabetic Neuropathy & Glycemic Swings

Impact of Glycemic Variability on Early Sweat Gland Dysfunction

Authors: Yang Ou, Xiao‐feng Hu, Zhi Liang, Xiao‐hui Zhang, Yi‐kun Zhou

Research Objective: To investigate how wide fluctuations in blood sugar (glycemic variability) affect sweat gland function in the hands and feet of patients with type 2 diabetes. Impaired sweat function (sudomotor dysfunction) is an early warning sign of diabetic peripheral nerve damage.

Methods: The researchers evaluated 206 patients with type 2 diabetes and 34 healthy individuals. Sweat function in the hands and feet was assessed using special conductivity tests. Diabetes patients also wore continuous glucose monitors (CGMs) to map out blood sugar fluctuations.

Main Findings: Patients with abnormal sweat function typically had diabetes for longer and suffered from wider blood sugar swings. Interestingly, a specific group of patients with "reversible" sweat gland damage showed high sensitivity to blood sugar control; keeping blood sugar levels steady between 5.0 and 10.0 mmol/L was linked with noticeable improvements in their sweat function.

Clinical Significance: Rapidly fluctuating blood sugar levels directly correlate with more severe nerve damage. Keeping blood sugar stable, specifically in the 5–10 mmol/L range, may protect and even restore early-stage nerve function.

Key point for patients: Avoiding dramatic peaks and valleys in your daily blood sugar, rather than just focusing on your average HbA1c, is crucial for preventing early nerve damage in your hands and feet.

DOI: https://doi.org/10.1111/jdi.70211

Diabetic Retinopathy & Genetics

Evaluating the Link Between White Blood Cell Counts and Diabetic Retinopathy

Authors: Yan Wang, Yunxian Gao, Zhiqiang Wang, Luhua Wu, Lixia Guo, Xiaoqiang Zhang, Jiaxin Wu, Shanshan Shang

Research Objective: To examine whether circulating white blood cells (leukocytes) play a direct, causal role in the development of diabetic retinopathy, a leading cause of vision loss.

Methods: The study used a sophisticated genetic comparison method called Mendelian randomization, drawing on data from large genomic studies of European populations to assess five types of white blood cells.

Main Findings: The genetic data showed that a higher count of a specific type of white blood cell, lymphocytes, is associated with a lower risk of developing diabetic retinopathy. Other cell types, such as neutrophils and monocytes, did not show a clear, robust causal relationship.

Clinical Significance: This study provides genetic evidence pointing toward the immune system's protective and active role in eye health, helping researchers narrow down specific inflammatory markers for future treatment targets.

Key point for patients: Your body's immune system and inflammatory responses are intricately linked with eye health. This research helps scientists understand how to protect blood vessels in the eye from diabetes-related damage.

DOI: https://doi.org/10.1111/jdi.70196

Clinical Trial Update

Phase IIa Evaluation of ONO-2910 for Diabetic Polyneuropathy

Authors: Yukiko Onishi, Takeshi Osonoi, Norio Takahashi, Toru Takiguchi, Eiichiro Morishima, Yoshimasa Aso, Kenji Sekiguchi, Hideki Kamiya, Jiro Nakamura

Research Objective: To evaluate the safety and clinical effectiveness of ONO-2910, a novel drug candidate designed to support nerve health by promoting helper-cell (Schwann cell) growth, in patients with diabetic polyneuropathy.

Methods: In a double-blinded clinical study, Japanese patients with type 2 diabetes and nerve pain/numbness were randomized to receive either 300 mg of ONO-2910 daily (76 patients) or a placebo (77 patients) for 12 weeks.

Main Findings: The drug was well-tolerated, with side effects being mild and similar to those who took the placebo (such as cold-like symptoms and mild diarrhea). However, after 12 weeks, there were no significant improvements in pain, numbness, or nerve impulse speeds compared to the placebo group.

Clinical Significance: While ONO-2910 has established a strong safety profile, a 12-week regimen did not show a therapeutic advantage over placebo for alleviating nerve symptoms. Future trials may need to explore different timelines or patient subgroups.

Key point for patients: Finding drugs to regenerate nerves remains a massive challenge. While this drug did not show improvement over placebo in this short study, it proved to be safe, opening doors for further investigations into neuropathy treatments.

DOI: https://doi.org/10.1111/jdi.70193

Personalized Medicine

Using Machine Learning to Predict Patient Response to Imeglimin

Authors: Katsuhiko Hagi, Kazumasa Yoshida, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki

Research Objective: To identify which patient-specific traits (like age, weight, and cholesterol levels) can predict a strong response to the diabetes medication imeglimin.

Methods: Researchers utilized machine learning algorithms to analyze data from three large clinical trials of imeglimin in Japan, looking at patients who took the drug on its own versus those who added it to existing insulin therapy.

Main Findings: For those taking imeglimin alone, nonsmokers with high baseline HbA1c (≥8.35%) and healthy LDL cholesterol levels achieved the greatest blood sugar drop. For patients taking it alongside insulin, older individuals with a lower BMI and lower liver enzymes (ALT) responded best.

Clinical Significance: This study demonstrates that advanced computing and artificial intelligence can help doctors "match" the right patient with the right medication, leading to better clinical success and highly personalized diabetes management.

Key point for patients: Not every diabetes drug works the same for everyone. In the future, your physician may use smart data tools to predict exactly how well a medication like imeglimin will work for you before you even start taking it.

DOI: https://doi.org/10.1111/jdi.70215

Lifestyle & COVID-19 Impact

How COVID-19 Containment Altered Body Composition in Adults with Diabetes

Authors: Yuko Yamaguchi, Yoshiyuki Hamamoto, Masahiro Imura, Yuichiro Yamada, Yutaka Seino

Research Objective: To observe how lifestyle restrictions, such as Japan's repeated COVID-19 states of emergency, influenced the body weight, muscle mass, and fat mass of people living with diabetes.

Methods: A retrospective study tracked 673 adults with diabetes across three periods: before the states of emergency, during them, and after they were lifted.

Main Findings: While patients' overall HbA1c (blood sugar average) remained remarkably stable, their physical body composition changed. All studied groups showed a continuous loss of skeletal muscle mass. Furthermore, older males experienced an increase in overall body fat percentage because their fat mass did not drop after restrictions ended, while their muscle continued to decline.

Clinical Significance: Prolonged periods of restricted physical activity can trigger "hidden" health risks like muscle loss (sarcopenia) and a rise in body fat percentage, even if your weight or laboratory blood sugar numbers appear stable.

Key point for patients: Staying active is about more than just managing your weight or blood sugar numbers. Protecting your muscles through resistance exercise is vital, especially for older men, during times when physical activity is restricted.

DOI: https://doi.org/10.1111/jdi.70197

Kidney Disease Research

Understanding the Role of PKM2 in Diabetic Kidney Disease and Cell Aging

Authors: Md. Imrul Kayes, Keizo Kanasaki

Research Objective: To review how changes in a specific enzyme called PKM2 (pyruvate kinase M2) affect kidney cell damage and aging (senescence) when exposed to chronic high blood sugar.

Methods: A detailed review of metabolic pathways, tracking how kidney cells process sugar under standard vs. hyperglycemic conditions.

Main Findings: Under long-term high blood sugar, the PKM2 enzyme shifts from its healthy, highly active form (tetramer) to a sluggish form (dimer). This sluggish form causes kidney cells to accumulate lactic acid and triggers cellular stress, inflammation, and cellular aging, which ultimately leads to kidney scarring and tissue damage.

Clinical Significance: Finding ways to stabilize PKM2 back into its healthy tetramer state could protect kidney cells from metabolic stress, offering a brand-new way to slow down or even reverse diabetic kidney disease (DKD).

Key point for patients: Scientists are looking deep inside our cells to find out why high blood sugar causes kidney wear-and-tear. Correcting how kidney cells burn sugar could prevent kidney damage in the future.

DOI: https://doi.org/10.1111/jdi.70231

Diabetes Technology

Upgrading to Advanced Insulin Pumps Improves Daily Treatment Satisfaction

Authors: Naoya Shimizu, Nozomi Ishimoto, Umeko Sakamoto, Mai Taneda, Akinori Hayashi, Takeshi Miyatsuka

Research Objective: To assess whether sequentially upgrading to more advanced, automated insulin pump systems truly increases patient satisfaction and improves overall blood sugar control in people with type 1 diabetes.

Methods: A retrospective study of patients with type 1 diabetes who upgraded from basic predictive low-glucose systems (MiniMed 640G) to early automated systems (770G), and finally to advanced hybrid closed-loop systems (780G). Satisfaction levels and glucose data were thoroughly compared.

Main Findings: While basic daily satisfaction scores remained relatively steady, patients reported a dramatic boost in overall comparative satisfaction after upgrading to the 780G advanced hybrid closed-loop pump. Along with feeling more satisfied, patients experienced lower HbA1c levels and spent more "time in range" (stable blood sugar ranges).

Clinical Significance: Newer "smart" insulin pump systems that automate correction doses do not just improve clinical metrics; they dramatically reduce the mental burden of diabetes, directly resulting in happier, more satisfied patients.

Key point for patients: If you are managing type 1 diabetes, upgrading to a modern "closed-loop" system (sometimes called an artificial pancreas) can give you better blood sugar control with significantly less daily hassle and stress.

DOI: https://doi.org/10.1111/jdi.70223

Innovative Diagnostics

Validating a Faster, Simpler Way to Diagnose Diabetic Nerve Damage

Authors: Tatsuhito Himeno, Hideki Kamiya, Yuka Shibata, Masato Kase, Hiromi Nakai‐Shimoda, Dai Yamagami, Masahiro Saito, Teruo Jojima, Aiko Arimura, Kenta Murotani, Chieko Suzuki, Hiroki Mizukami, Takahisa Deguchi, Yoshimasa Aso, Jiro Nakamura

Research Objective: To test if combining two rapid, simple tests—measuring minor variations in heart rate and using a quick hand-held nerve conduction device—can diagnose diabetic polyneuropathy (DPN) as accurately as complex, time-consuming hospital testing equipment.

Methods: A retrospective study of 314 patients compared results from classic, high-end electromyography machines against simple diagnostic tools: heart rate rhythm variation (CV_R-R) and a point-of-care nerve testing device (NC-stat/DPNCheck™).

Main Findings: Combining these two simple, quick tests provided diagnostic results that highly agreed with the older, complex, and expensive laboratory nerve conduction methods.

Clinical Significance: Objective nerve testing is vital because subjective symptoms do not always match actual physical nerve damage. Having a fast, reliable, and portable way to test nerves in ordinary clinics can help doctors spot and treat diabetic neuropathy years before it becomes severe.

Key point for patients: If you are concerned about nerve damage (numbness, pain, or tingling), ask your clinic about quick, portable nerve testing methods that do not require complex, uncomfortable hospital visits.

DOI: https://doi.org/10.1111/jdi.70190

New Discoveries in Diabetes: Uncovering Pathways, Risk Factors, and Personalized Care

Journal of Diabetes Investigation: Vol. 17, Issue 1 (2026)

Issue (JDI Vol.17, Issue1) Summary

This issue of the Journal of Diabetes Investigation presents a diverse collection of research, offering significant advancements across various facets of diabetes care and understanding. Key themes include uncovering fundamental mechanisms of type 1 diabetes progression, identifying age-specific differences in diabetic foot ulcers, exploring the broader benefits of SGLT2 inhibitors, and pinpointing novel risk markers for metabolic liver and cardiovascular disease in individuals with type 2 diabetes.

Particularly notable studies in this issue shed light on the intricate molecular pathways contributing to beta-cell loss in type 1 diabetes, potentially opening doors for new protective therapies. Another study highlights the critical need for age-tailored prevention and treatment strategies for diabetic foot ulcers, emphasizing that 'one size does not fit all' in managing this severe complication.

For patients and families, these findings offer insights into the complex nature of diabetes and its complications. The research underscores the importance of personalized care, from understanding individual risk factors for foot complications and liver disease to recognizing the wide-ranging benefits of existing medications like SGLT2 inhibitors. It also provides a glimpse into future therapeutic possibilities for preserving insulin-producing cells in type 1 diabetes.

Collectively, this issue’s papers have strong implications for future diabetes research and care, paving the way for more targeted interventions, improved risk assessment tools, and ultimately, enhanced quality of life for individuals living with diabetes.

Disclaimer

The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Individual Paper Reviews

Uncovering a Key Pathway in Type 1 Diabetes: PLAGL1 and Beta-Cell Destruction

Research Objective

This study aimed to understand how a gene called PLAGL1 contributes to the destruction of insulin-producing beta-cells in type 1 diabetes (T1DM), specifically investigating its role in oxidative stress, DNA damage, and inflammatory pathways.

Methods

Researchers used mouse beta-cells (NIT-1 line) to either increase or decrease PLAGL1 levels. They then measured DNA damage, oxidative stress markers, and indicators of beta-cell death. They also tested specific inhibitors for the cGAS/STING pathway, a known inflammatory response. Finally, they studied PLAGL1 overexpression in NOD mice (a model for T1DM) and observed the effects of cGAS/STING inhibition on glucose control and pancreatic beta-cell health.

Main Findings

The study found that increased PLAGL1 led to significant DNA damage in beta-cells, heightened oxidative stress, and impaired DNA repair. This resulted in the accumulation of damaged DNA, which activated an inflammatory pathway called cGAS/STING, ultimately causing beta-cell death and reduced insulin production. When this cGAS/STING pathway was blocked, beta-cell death was reduced, and insulin secretion improved in both cell cultures and diabetic mice. In mice, inhibiting this pathway also helped preserve beta-cell mass and improve blood sugar control.

Clinical Significance

This research identifies PLAGL1 as a key player in exacerbating beta-cell loss in type 1 diabetes by triggering a harmful cycle of oxidative DNA damage and inflammation. Targeting the cGAS/STING pathway offers a promising new therapeutic strategy to protect beta-cells and slow down the progression of T1DM.

Key Points for Patients

This study helps us understand more about why the body's own immune system attacks insulin-producing cells in type 1 diabetes. It suggests that future treatments might focus on blocking specific inflammatory pathways to protect these vital cells, potentially slowing down or even preventing the progression of type 1 diabetes.

DOI: https://doi.org/10.1111/jdi.70204

Diabetic Foot Ulcers: Clinical Characteristics Vary by Age

Research Objective

This study aimed to investigate how the clinical characteristics of diabetic foot ulcers (DFUs) differ among diabetic patients of various age groups.

Methods

Researchers conducted a retrospective study on 1,209 diabetic patients with foot ulcers. Patients were divided into young (<45 years), middle-aged (45-64 years), and elderly (≥65 years) groups. They analyzed patient data including diabetes duration, glycemic control, ulcer type, presence of other health conditions (comorbidities), ulcer healing rates during hospitalization, and all-cause mortality over a median follow-up of 44.5 months.

Main Findings

The study found that DFU characteristics are significantly age-dependent. Younger patients often had poorer blood sugar control, nerve-related (neuropathic) ulcers, and injuries due to mechanical stress. In contrast, older patients had more vascular complications (like peripheral artery disease) and ulcers that were a combination of nerve and circulation issues (neuro-ischemic). The prevalence of other health conditions like hypertension and kidney disease increased with age. Elderly patients also had significantly lower ulcer healing rates during hospitalization and higher mortality rates compared to younger and middle-aged groups.

Clinical Significance

These findings highlight that prevention and treatment strategies for diabetic foot ulcers need to be tailored to the patient's age. Understanding these age-related differences can lead to more effective, personalized care plans.

Key Points for Patients

If you have diabetes and a foot ulcer, it's important to know that your age can influence the type of ulcer you might have and how it heals. Younger individuals might face challenges with blood sugar control and nerve damage, while older individuals may have more circulation problems. Your healthcare team can use this information to create a more personalized plan for preventing and treating foot ulcers.

DOI: https://doi.org/10.1111/jdi.70181

SGLT2 Inhibitors Boost Hemoglobin Levels, Even with Chronic Inflammation

Research Objective

This study aimed to determine if chronic inflammation affects the ability of sodium-glucose co-transporter 2 inhibitors (SGLT2is) to increase hemoglobin levels in patients with diabetes.

Methods

A matched-pair cohort study was conducted with diabetic patients. New users of SGLT2is were compared to those who had never used them. Patients were grouped based on their levels of C-reactive protein (CRP), a marker of inflammation. Hemoglobin (Hb), CRP, and mean corpuscular volume (MCV) changes were tracked over time.

Main Findings

The study found that SGLT2 inhibitor use was associated with higher hemoglobin levels, regardless of whether patients had chronic inflammation or not. In fact, during the first six months, the increase in hemoglobin among SGLT2i users was even more noticeable in those with higher levels of inflammation. While hemoglobin increased, CRP levels remained stable, and MCV (red blood cell size) increased in SGLT2i users with higher CRP.

Clinical Significance

This research confirms that SGLT2 inhibitors can effectively increase hemoglobin levels in patients with diabetes, and this benefit is not diminished by the presence of chronic inflammation. This adds to the understanding of the broad positive effects of SGLT2is beyond blood sugar control.

Key Points for Patients

If you are taking an SGLT2 inhibitor for your diabetes, this study indicates that it can help improve your hemoglobin levels (a measure of red blood cells), which is beneficial for overall health. This positive effect appears to hold true even if you have ongoing inflammation in your body.

DOI: https://doi.org/10.1111/jdi.70189

Hormone Ratio Linked to Liver Disease Risk in Men with Type 2 Diabetes

Research Objective

This study aimed to explore the relationship between the ratio of estradiol to testosterone (E2/T ratio) and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, in men with type 2 diabetes mellitus (T2DM).

Methods

This observational study included 1,441 male patients with type 2 diabetes. MASLD was diagnosed using abdominal ultrasonography. Researchers compared the clinical characteristics and prevalence of MASLD across different quartiles (four equal groups) of the E2/T ratio. Statistical methods, including binary logistic regression, were used to assess the association between the E2/T ratio and MASLD, adjusting for factors like age and diabetes duration.

Main Findings

The study found that as the E2/T ratio increased, the prevalence of MASLD significantly increased in men with type 2 diabetes (from 37.7% in the lowest quartile to 69.3% in the highest). After adjusting for other factors, a higher E2/T ratio was independently associated with an increased risk of MASLD. Additionally, patients with MASLD had higher levels of C-reactive protein (CRP), an inflammation marker, and CRP levels also increased with a higher E2/T ratio.

Clinical Significance

The E2/T ratio could serve as a simple and practical indicator to assess the risk of MASLD in men with type 2 diabetes. This association might be linked to the role of the E2/T ratio in inflammation, suggesting a potential pathway for intervention or risk stratification.

Key Points for Patients

For men with type 2 diabetes, the balance of certain hormones (estradiol and testosterone) might be an important clue to your risk for developing fatty liver disease (MASLD). A higher ratio of estradiol to testosterone was linked to a greater risk. Your doctor might consider checking this ratio as part of assessing your liver health and overall risk.

DOI: https://doi.org/10.1111/jdi.70202

Different Markers Predict Different Types of Early Heart Dysfunction

Research Objective

This study aimed to compare how two measures of insulin resistance—the triglyceride-glucose (TyG) index and the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)—relate to early, subtle signs of left ventricular (main pumping chamber of the heart) dysfunction in the general population.

Methods

The study recruited 2,850 participants with normal heart pumping function (ejection fraction ≥50%). They used an advanced ultrasound technique called speckle-tracking echocardiography to measure global longitudinal strain (GLS), which detects subtle changes in heart muscle contraction, and other indicators of heart function. Subclinical left ventricular systolic dysfunction (LVSD) was defined as GLS <18%.

Main Findings

Both higher TyG index and HOMA-IR were initially linked to reduced overall heart function. However, after accounting for other influencing factors, HOMA-IR was more strongly associated with subtle left ventricular systolic dysfunction (measured by GLS). In contrast, the TyG index showed a stronger relationship with early diastolic dysfunction, which is when the heart muscle has trouble relaxing and filling with blood properly (measured by the E/e' ratio). The study found that individuals with the highest HOMA-IR levels had more than double the odds of having subclinical LVSD, while the TyG index did not show a significant association with LVSD prevalence.

Clinical Significance

This research suggests that the TyG index and HOMA-IR might reflect different aspects of insulin resistance and its impact on heart function. HOMA-IR appears to be a better predictor for early issues with the heart's pumping ability (systolic dysfunction), while the TyG index is more closely related to problems with the heart's relaxation and filling (diastolic dysfunction). This distinction could help healthcare providers use these markers more effectively for early detection and risk assessment.

Key Points for Patients

If you have or are at risk for diabetes, your doctor might use different calculations (like the TyG index or HOMA-IR) to understand your insulin resistance. This study shows that these different measures might predict different types of early heart problems. For example, HOMA-IR might be better at detecting subtle issues with your heart's pumping strength, while the TyG index might be more useful for identifying early problems with how your heart relaxes and fills. This helps doctors get a more complete picture of your heart health.

DOI: https://doi.org/10.1111/jdi.70201